Martin Schlumberger
马丁·施隆贝格尔
MD
Professor of Oncology and Head, Department of Nuclear Medicine and Endocrine Oncology肿瘤学教授兼核医学与内分泌肿瘤科主任
👥Biography 个人简介
Global authority in thyroid cancer systemic therapy and clinical trials. Led pivotal trials of vandetanib and cabozantinib in medullary thyroid cancer and conducted landmark studies of lenvatinib and sorafenib in differentiated thyroid cancer, shaping worldwide treatment standards.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Thyroid Cancer Systemic Therapy Trials
Led or co-led multiple landmark phase 3 trials in differentiated and medullary thyroid cancer—including SELECT (lenvatinib) and ZETA (vandetanib)—that led to drug approvals and transformed the therapeutic landscape.
Representative Works 代表性著作
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial
Journal of Clinical Oncology (2012)
ZETA trial establishing vandetanib as the first approved therapy for advanced medullary thyroid cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 马丁·施隆贝格尔 的研究动态
Follow Martin Schlumberger's research updates
留下邮箱，当我们发布与 Martin Schlumberger（Gustave Roussy Cancer Campus）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment